Nutriband Inc. Achieves Milestone in Development of Abuse-Deterrent Fentanyl

Nutriband Inc. (NASDAQ: NTRB) has reached a pivotal moment in the development of AVERSA™ Fentanyl, completing commercial-scale manufacturing in collaboration with Kindeva Drug Delivery. This achievement not only brings the product closer to FDA approval but also highlights the potential of AVERSA's abuse-deterrent technology to revolutionize pain management amidst the ongoing opioid crisis. The technology, designed to deter abuse while maintaining medical efficacy, could play a crucial role in combating the dangers posed by synthetic opioids like fentanyl.

The significance of this development is further underscored by Nutriband's recent inclusion in four key indexes, including the Russel Indexes, and an updated analyst report that raises NTRB’s price target to $15.00. These milestones reflect the growing confidence in Nutriband's strategic direction and its ability to execute on its vision. AVERSA's technology, protected by international patents, stands as a testament to the company's innovative approach to addressing one of the most pressing healthcare challenges today.

As the healthcare community continues to seek solutions to the opioid epidemic, the progress of AVERSA™ Fentanyl offers hope for a future where pain management does not come at the expense of safety. For more information on Nutriband Inc. and its developments, visit https://www.nutriband.com. The completion of commercial-scale manufacturing for AVERSA™ Fentanyl is a critical step forward in the fight against opioid abuse, showcasing Nutriband's commitment to innovation and patient safety.